652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

• Cara Haymaker,
• Aung Naing,
• Minal Barve,
• Marya Chaney,
• Se Hwan Yang,
• Siyoung Lee,
• Byung Ha Lee,
• Sara Ferrando-Martinez,
• Hirva Mamdani,
• Richard D Kim,
• Meredith Pelster,
• Mohamed Derbala,
• Jack Goon,
• Samuel Darko,
• Julie Murphy,
• Lauren Gorelik,
• Allison Bierly

Affiliations

Cara Haymaker

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Aung Naing

10The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Minal Barve

3Mary Crowley Cancer Research, Dallas, TX, USA

Marya Chaney

19Merck and Co., Inc, Rahway, NJ, USA

Se Hwan Yang

5NeoImmuneTech, Inc., Rockville, MD, USA

Siyoung Lee

6Geninus Inc., Seoul, Republic of Korea

Byung Ha Lee

5NeoImmuneTech, Inc., Rockville, MD, USA

Sara Ferrando-Martinez

5NeoImmuneTech, Inc., Rockville, MD, USA

Hirva Mamdani

2Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA

Richard D Kim

8Moffitt Cancer Center, Tampa, FL, USA

Meredith Pelster

4Sarah Cannon Research Institute, Nashville, TN, USA

Mohamed Derbala

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jack Goon

5NeoImmuneTech, Inc., Rockville, MD, USA

Samuel Darko

5NeoImmuneTech, Inc., Rockville, MD, USA

Julie Murphy

5NeoImmuneTech, Inc., Rockville, MD, USA

Lauren Gorelik

5NeoImmuneTech, Inc., Rockville, MD, USA

Allison Bierly

5NeoImmuneTech, Inc., Rockville, MD, USA